TT-173(TT-173) - 药物靶点：tissue factor_在研适应症：凝血障碍，手术失血，创伤和损伤_专利_临床

概要

基本信息

药物类型

重组凝血因子

别名

靶点

tissue factor

作用机制

tissue factor调节剂(组织因子调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 8396

关联

3

项与 TT-173 相关的临床试验

NCT02687399 / Unknown status临床2/3期

A Phase II/III, Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of Topically Applied TT-173 in Patients Undergoing Knee Arthroplasty

The purpose of this study is to determine the haemostatic efficacy of TT-173, reducing the total blood loss associated with the total knee arthroplasty.

开始日期2016-01-01

申办/合作机构

Thrombotargets Corp.

NCT02012569 / Completed临床2期

A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft

The purpose of this study is to determine the haemostatic efficacy of TT-173, reducing the bleeding time in the donor site of skin grafting.

开始日期2013-11-01

申办/合作机构

Thrombotargets Corp.

NCT01595360 / Completed临床1期

A Phase 1, Randomized, Open, Controlled, Comparative Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction

The purpose of this study is to evaluate the safety, tolerability and efficacy of TT-173 in healthy volunteers after tooth extraction.

开始日期2012-04-01

申办/合作机构

Thrombotargets Corp.

100 项与 TT-173 相关的临床结果

登录后查看更多信息

100 项与 TT-173 相关的转化医学

登录后查看更多信息

100 项与 TT-173 相关的专利（医药）

登录后查看更多信息

8

项与 TT-173 相关的文献（医药）

2023-03-02·Journal of Burn Care & Research

Topical Hemostatic Agents in Burn Surgery: A Systematic Review

Review

作者: Battistini, Andrea ; Gottlieb, Lawrence J ; Vrouwe, Sebastian Q

AbstractAcute burn surgery has long been associated with significant intra-operative bleeding. Several techniques were introduced to limit hemorrhage, including tourniquets, tumescent infiltration, and topical agents. To date, no study has comprehensively investigated the available data regarding topical hemostatic agents in burn surgery. A systematic review was performed by two independent reviewers using electronic databases (PubMed, Scopus, Web of Science) from first available to September 10, 2021. Articles were included if they were published in English and described or evaluated topical hemostatic agents used in burn excision and/or grafting. Data were extracted on the agent(s) used, their dosage, mode of delivery, hemostasis outcomes, and complications. The search identified 1982 nonduplicate citations, of which 134 underwent full-text review, and 49 met inclusion criteria. In total, 32 studies incorporated a vasoconstrictor agent, and 28 studies incorporated a procoagulant agent. Four studies incorporated other agents (hydrogen peroxide, tranexamic acid, collagen sheets, and TT-173). The most common vasoconstrictor used was epinephrine, with doses ranging from 1:1000 to 1:1,000,000. The most common procoagulant used was thrombin, with doses ranging from 10 to 1000 IU/ml. Among the comparative studies, outcomes of blood loss were not reported in a consistent manner, therefore meta-analysis could not be performed. The majority of studies (94%) were level of evidence III–V. Determining the optimal topical hemostatic agent is limited by low-quality data and challenges with consistent reporting of intra-operative blood loss. Given the routine use of topical hemostatic agents in burn surgery, high-quality research is essential to determine the optimal agent, dosage, and mode of delivery.

2020-04-20·Journal of Investigative Surgery4区 · 医学

Experimental Evaluation of a New Tissue Factor-Based Topical Hemostat (TT-173) for Treatment of Hepatic Bleeding

4区 · 医学

Article

作者: Arias, Belén ; Ureta, Claudia ; López, Ramón ; Rojas, Santiago ; Murat, Jesús ; Sánchez, Pilar ; Centeno, Alberto ; Miquel, Ignasi ; Rincón, Esther

Background: Excessive blood loss is a relevant complication of partial liver resection. Topical hemostatic agents have proven useful to improve the control of the bleeding in this among other surgical indications. Until now all of these products have been based on the action of thrombin. In contrast TT-173 is a new topical hemostatic agent based on recombinant tissue factor naturally incorporated into membrane vesicles. This work sought to assess the efficacy and toxicity of TT-173 in an animal model of liver resection.Materials and Methods: Procoagulant activity of 0.15, 0.41, and 1 mg of TT-173 was evaluated in pigs subjected the resection of hepatic lobe margins. The most effective of these doses was also compared against thrombin. In addition, the toxicity, local tolerance, systemic absorption, and immunogenicity of the product were investigated in rats subjected to liver biopsy lesion.Results: The three doses of TT-173 evaluated significantly reduced the bleeding time in liver lesions. The highest dose of product was significantly more effective than the others and thrombin. Application of high doses of TT-173 in rats did not cause any local or systemic alterations. Absorption into blood stream was negligible and no immunogenic reaction against the product was detected.Conclusions: TT-173 shows favorable pharmacodynamic properties for improving hemostasis in partial liver resection which support further investigation of the product in this surgical indication.

2017-12-01·The Knee4区 · 医学

A new topical hemostatic agent TT-173 reduces blood loss in a sheep model of total knee arthroplasty

4区 · 医学

Article

作者: Miquel, Ignasi ; Sánchez, Pilar ; Rincón, Esther ; Ureta, Claudia ; López, Ramón ; Centeno, Alberto ; Arias, Belén ; Murat, Jesús ; Rojas, Santiago

BACKGROUNDTotal knee arthroplasty is associated with blood loss during the intervention and may require allogenic blood transfusion. Treatments such as tranexamic acid and fibrin sealants improved the bleeding control in several clinical trials, but the hemorrhage associated with the intervention is still significant. Thus far, very few studies have evaluated hemostatic treatments in animal models of total knee arthroplasty. This work describes a sheep model of bleeding associated with total knee arthroplasty and investigates a new class of hemostatic treatment based on recombinant tissue factor.METHODSSheep were treated with the anticoagulant heparin, and the joint was accessed by a paramedial incision. Ligaments and menisci were eliminated and femoral condyles and tibia plateau were sectioned exposing the trabecular bone. An intra-articular drain was used to recover and quantify the blood loss during the 90-min period after treatment. The efficacy of one milligram and three milligrams of TT-173 was evaluated and compared with tranexamic acid. The occurrence of analytical alterations and systemic absorption was also investigated.RESULTSTreatment with TT-173 reduced the blood loss in comparison with control or tranexamic acid. No significant differences were observed between the two doses evaluated. Moreover, a dose of six milligrams of TT-173 did not induce any clinical or analytical alteration, and significant systemic absorption was not observed.CONCLUSIONData obtained strongly suggest that TT-173 could be useful in reducing the blood loss associated with total knee arthroplasty and without safety concerns derived from the systemic absorption of the product.

100 项与 TT-173 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
凝血障碍	临床3期	-	Thrombotargets Corp.	-
手术失血	临床2期	美国	Protheragen, Inc.	2022-01-30
创伤和损伤	临床2期	美国	Protheragen, Inc.	2022-01-30
出血	药物发现	西班牙	Thrombotargets Corp.	2016-01-01
骨关节炎	药物发现	西班牙	Thrombotargets Corp.	2016-01-01
烧伤	药物发现	西班牙	Thrombotargets Corp.	2013-11-01